Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety\/Tolerability\/PK\/PD Trial of EVX-301","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX\u2011101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Evecxia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evecxia Therapeutics Reports Favorable Data from a Phase 1 SAD\/MAD Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Evecxia Therapeutics

    Menu

    Evecxia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101

              Details:

              EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.

              Lead Product(s): HSDB 4295,Carbidopa

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

              Details:

              EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.

              Lead Product(s): HSDB 4295,Carbidopa

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Quotient Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX‑101

              Details:

              EVX-101 is a proprietary, oral tablet, gastroretentive, slow-release formulation of 5-HTP and low-dose carbidopa. It is being developed for patients with depression responding inadequately to first-line SSRI/SNRI antidepressants monotherapy.

              Lead Product(s): HSDB 4295,Carbidopa

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With ...

              Details:

              EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin, and low-dose carbidopa. It is being investegated for major depressive disorder.

              Lead Product(s): HSDB 4295,Carbidopa

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Reports Favorable Data from a Phase 1 SAD/MAD Trial

              Details:

              EVX-101 is a novel, proprietary gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin. It is under phase 1 clinical trials for the treatment of major depressive disorder.

              Lead Product(s): HSDB 4295,Carbidopa

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301

              Details:

              EVX-301 (5-hydroxytryptophan) is designed to quickly and optimally amplify brain extracellular serotonin and hence serotonin neurotransmission, as a rescue therapy for patients hospitalized for acute suicidal ideation crisis.

              Lead Product(s): EVX-301

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-301

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Evecxia Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders

              Details:

              EVX-101 is a clinical-stage drug candidate currently being developed as an adjunctive treatment for when first-line antidepressants alone are inadequate.

              Lead Product(s): EVX-101

              Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY